Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Investigating the Safety and Feasibility of Peptide GAM Immunoadsorption in Anti-PLA2R Positive Autoimmune Membranous Nephropathy

NCT03255447 is registered in ClinicalTrials.gov with Manchester University NHS Foundation Trust as lead sponsor.

NCT NCT03255447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03255447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Investigating the Safety and Feasibility of Peptide GAM Immunoadsorption in Anti-PLA2R Positive Autoimmune Membranous Nephropathy
Lead sponsor
Manchester University NHS Foundation Trust
Phase
Not applicable
Overall status
Completed
Start date
November 30, 2016
Completion date
April 3, 2019
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune membranous nephropathy